Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma

Barcelona clinic liver cancer (BCLC) intermediate stage hepatocellular carcinoma is a heterogenous disease. Transarterial chemoembolization is offered as the first line therapy in this disease stage. Recent advances in systemic therapy have markedly improved outcomes even in advanced stage disease....

Descripción completa

Detalles Bibliográficos
Autores principales: Silk, Tarik, Silk, Mikhail, Wu, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Minireviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254139/
https://www.ncbi.nlm.nih.gov/pubmed/35949352
http://dx.doi.org/10.3748/wjg.v28.i23.2561
_version_ 1784740629628059648
author Silk, Tarik
Silk, Mikhail
Wu, Jennifer
author_facet Silk, Tarik
Silk, Mikhail
Wu, Jennifer
author_sort Silk, Tarik
collection PubMed
description Barcelona clinic liver cancer (BCLC) intermediate stage hepatocellular carcinoma is a heterogenous disease. Transarterial chemoembolization is offered as the first line therapy in this disease stage. Recent advances in systemic therapy have markedly improved outcomes even in advanced stage disease. The use of systemic therapy in BCLC intermediate stage disease may now be of therapeutic benefit in selected patients. We will focus on “the up to seven” criteria and its utility in selecting systemic therapy.
format Online
Article
Text
id pubmed-9254139
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-92541392022-08-09 Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma Silk, Tarik Silk, Mikhail Wu, Jennifer World J Gastroenterol Minireviews Barcelona clinic liver cancer (BCLC) intermediate stage hepatocellular carcinoma is a heterogenous disease. Transarterial chemoembolization is offered as the first line therapy in this disease stage. Recent advances in systemic therapy have markedly improved outcomes even in advanced stage disease. The use of systemic therapy in BCLC intermediate stage disease may now be of therapeutic benefit in selected patients. We will focus on “the up to seven” criteria and its utility in selecting systemic therapy. Baishideng Publishing Group Inc 2022-06-21 2022-06-21 /pmc/articles/PMC9254139/ /pubmed/35949352 http://dx.doi.org/10.3748/wjg.v28.i23.2561 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Minireviews
Silk, Tarik
Silk, Mikhail
Wu, Jennifer
Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma
title Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma
title_full Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma
title_fullStr Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma
title_full_unstemmed Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma
title_short Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma
title_sort up to seven criteria in selection of systemic therapy for hepatocellular carcinoma
topic Minireviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254139/
https://www.ncbi.nlm.nih.gov/pubmed/35949352
http://dx.doi.org/10.3748/wjg.v28.i23.2561
work_keys_str_mv AT silktarik uptosevencriteriainselectionofsystemictherapyforhepatocellularcarcinoma
AT silkmikhail uptosevencriteriainselectionofsystemictherapyforhepatocellularcarcinoma
AT wujennifer uptosevencriteriainselectionofsystemictherapyforhepatocellularcarcinoma

Ejemplares similares